Recent cancer research
And events from nci-funded research and ing smoking cessation at nci-designated cancer tive is aimed at helping cancer patients to stop trial cancer incidence on the ses of endometrial cancer have increased n cancer vaccine shows promise in experimental vaccine targets a protein found at elevated levels in most ovarian press sharpless sworn in as director of the national cancer e. He comes to nci from the university of north carolina school of medicine, where he was director of the lineberger comprehensive cancer -funded tmist study compares 2-d and 3-d mammography for finding breast , the first randomized trial comparing two types of digital mammography for breast cancer screening, is enrolling participants. Schiller of the national cancer institute receive the 2017 lasker-debakey clinical medical research award for their significant research leading to the development of hpv study identifies essential genes for cancer immunotherapy. New nci study identifies genes in cancer cells that are necessary for them to be killed by t cells, and therefore could be partially responsible for why immunotherapy doesn’t work in some study shows feasibility of cancer screening protocol for patients with li-fraumeni syndrome. New nci study demonstrates the feasibility of a comprehensive screening protocol for patients with li-fraumeni syndrome, a rare inherited disorder that leads to a higher risk of developing certain -cog pediatric match trial to test targeted drugs in childhood nationwide precision medicine trial will enroll children and adolescents with advanced cancers that haven’t responded to standard therapy to explore treatments targeted at specific genetic study of liver cancer reveals potential targets for two drugs are fda-approved for liver cancer. New study shows that the number of women in the united states living with distant metastatic breast cancer (mbc), the most severe form of the disease, is growing. Population and improvements in report to the nation: cancer death rates continue to ing to the latest annual report to the nation on the status of cancer, 1975-2014, overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups. But more work remains for some launches study of african-american cancer detroit research on cancer survivors (rocs) study, which will include 5,560 cancer survivors, will look at the major factors affecting cancer progression, recurrence, mortality, and quality of life among african-american cancer international media @ncimedia nci youtube subscribe to nci news currents find the latest news and research updates from the national cancer institute. Latest blog posts ific meetings and othock skea trust donates £5,000 to worldwide cancer researchnovember 24, 2017trustees from the aberbrothock skea trust have kindly donated £5,000 to worldwide cancer research to allow the charity to continue funding and discovering pioneering research mclaren from the trust visited the jacqui wood cancer centre based at ninewells hospital in dundee to hand ... Moreleading ip firm raise £2,607 for worldwide cancer research after completing tough 2,000km cycle challengenovember 22, 2017read morestomach microbiome implicated in varying risk of stomach tumoursnovember 3, 2017read morecelebrating women in scienceoctober 10, 2017read morethe dragons’ den-style contest to fund cancer researchseptember 25, 2017read moretargeting molecular ‘hooks’august 28, 2017read moregroundbreaking research allows scientists to visualise where aggressive skin cancer melanoma will spread, opening doors for new treatmentsjuly 26, 2017read moreskin cancer research project we kick-started gets the boost it needsjuly 25, 2017read morefirst 3d structure of the mini ‘cargo transporters’ inside our cellsjuly 5, 2017read morea new insight into how some cancers beginjune 15, 2017read out cancercancer of cancer al trials nci-supported clinical to find a clinical with clinical trials are clinical trials? To z list of cancer approved for different types of approved for conditions related to -label drug use in cancer mentary & alternative medicine (cam). For health ons to ask about your biopsy: using dna in blood to detect, track, and treat cancer. 2017research studies show tests that analyze tumor dna in blood, called liquid biopsies, may help detect cancer early, guide precision cancer treatment, and track treatment and sequence critical for immunotherapy combination.
2017when given at the same time, two immune checkpoint inhibitors were ineffective against breast cancer growth in mice, a new study found. The combination was more effective and safer if the two inhibitors were given in a specific ng conventional cancer treatments for alternative medicine increases risk of death. 2017in a large study, patients with nonmetastatic breast, lung, or colorectal cancer who chose alternative therapies had substantially worse survival than patients who received conventional cancer therapy: using the immune system to treat cancer. 2017immunotherapies are treatments that restore or enhance the immune system’s natural ability to fight cancer. In just the past few years, the rapidly advancing field of cancer immunology has produced several new methods of treating cancer that increase the strength of immune responses against t cells: engineering patients’ immune cells to treat their cancers. 2017car t-cell therapy is a rapidly emerging form of cancer treatment, primarily for blood cancers like leukemia and lymphoma. An article about research to improve car t-cell therapy and expand its uncovers previously unrecognized effect of chemotherapy. 2017a new study conducted primarily in mice suggests that chemotherapy given before surgery for breast cancer can cause changes in cells in and around the tumor that are tied to an increased risk of the cancer spreading to other areas of the study identifies essential genes for cancer immunotherapy. 2017a new nci study identifies genes in cancer cells that are necessary for them to be killed by t cells, and therefore could be partially responsible for why immunotherapy doesn’t work in some clears wider use of cooling cap to reduce hair loss during chemotherapy. 2017the fda has cleared a cooling cap—a device designed to reduce hair loss during chemotherapy called the dignicap scalp cooling system—for use by patients with any type of solid researchers report progress in studying exceptional responders. 2017researchers who study exceptional responders—patients who have dramatic and long-lasting responses to treatments for cancer that were not effective for most similar patients—met recently to discuss the state of the science in this emerging approves pembrolizumab for tumors with specific genetic features. This is the first approval based on a genetic feature, rather than cancer almanac: a new tool for research on cancer drug combinations. 2017nci has released a new, easy-to-use resource called the nci almanac to help researchers identify potentially promising combinations of cancer tion of patient-reported outcomes feasible in cancer clinical trials.
2017cancer patients, even those who are undergoing difficult treatments, are willing to devote time to completing thorough assessments of the side effects they encounter in clinical trials, a new study tanding “chemobrain” and cognitive impairment after cancer treatment. 2017researchers are investigating factors that might predict who’s more at risk for experiencing “chemobrain” after cancer treatment and what can be done to lessen its -cell based tool may help measure heart toxicity of cancer drugs. 2017researchers have used adult stem cells to create a tool for ranking how toxic a group of cancer drugs, called tyrosine kinase inhibitors, are to human heart cells. 2017using a new tool for editing genomes, known as crispr, researchers have genetically engineered immune cells and improved the ability of these cells to kill cancer cells in shows platelets can deliver immunotherapy, reduce tumor regrowth. 2017in experiments in mice, researchers show platelets linked to an immunotherapy drug can help eliminate residual cancer cells that remain after surgery. The engineered platelets may also prevent leftover cancer cells from ial new cancer therapy could target tumors two ways. 2017a team of researchers has developed a potential new therapy that may work in two distinct ways to attack tumors, by directly killing cancer cells and immune cells that can suppress the anti-cancer immune nib relieves chronic graft-versus-host disease symptoms. 2017the targeted cancer therapy ibrutinib can effectively treat the symptoms of chronic graft-versus-host disease, a common and serious complication of allogeneic stem cell transplants, findings from a small clinical trial fying novel drug combinations to overcome treatment resistance. Scientists are exploring combinations of different cancer drugs that have the potential to kill more cancer cells and overcome or delay drug ar immunotherapy targets a common human cancer mutation. 2016in a study of an immune therapy for colorectal cancer that involved a single patient, researchers identified a method for targeting the cancer-causing protein produced by a mutant form of the kras uses cancer cells' mass to predict response to treatment. 2016scientists have designed a device that measures the mass of single cancer cells to predict how cells respond to drug treatment. The technology could potentially help clinicians determine whether a drug effectively kills cancer ing patients about genetic test results: an interview with carol weil about the comet study. 2016the recently launched comet study will examine whether educating patients with cancer about genetic testing will increase their knowledge and reduce their stress levels after receiving genomic testing somal instability score may predict response to cancer treatment.
2016a drug currently used to treat several psychiatric conditions can help prevent nausea and vomiting in patients receiving chemotherapy, a large clinical trial x toxin-based cancer therapy targets tumor blood vessels. 2016a therapy that uses the anthrax toxin selectively targets blood vessels that feed tumors and support their growth and spread, researchers have -stage cancer trials support promise of precision medicine, immunotherapy. 2016the cfh antibodies killed tumor cells in cell lines of several cancer types and slowed tumor growth in mouse models of brain and lung cancer, without evidence of side ed photoimmunotherapy approach for cancer moves forward. 2016two new studies from nci researchers add to growing evidence of the promise of a novel type of cancer immunotherapy that uses infrared light to activate rapid and selective killing of cancer rticle generator slips chemotherapy past tumor cells’ protective barriers. 2016researchers have developed a new injectable nanoparticle-generating technology that can deliver a cancer drug to the nucleus of metastatic breast cancer tent peripheral neuropathy increases fall risk among cancer survivors. 2016many female cancer survivors have problems with mobility and other physical functioning as a result of persistent peripheral neuropathy caused by chemotherapy treatment, according to a new ng in on cancer checkpoint inhibitors. James gulley discusses cancer checkpoint inhibitors, their impact on patient care, and future directions for these ng cancer without harming the heart. 2015some cancer treatments may damage the heart, and researchers from the fields of oncology and cardiology are working to find ways to prevent, manage, and possibly even reverse these side identifies new opportunities for targeted immunotherapy. 2015a team of nci researchers has reported that several types of gastrointestinal cancer have tumor-specific mutations that can be recognized by the immune system, thereby offering a new therapeutic opportunity for patients with these approves rolapitant to prevent nausea and vomiting from chemotherapy. 2015the fda has approved rolapitant to prevent chemotherapy-induced nausea and eral damage: missing tumor suppressor gene creates opening for cancer treatment. 2015tumor cells that are missing one copy of the tumor suppressor gene tp53 often harbor another genetic alteration that may make them susceptible to a targeted attack, according to a new patients will benefit from immunotherapy for cancer? 2014researchers have identified a “genetic signature” in the tumors of patients with advanced melanoma who responded to a form of immunotherapy called checkpoint blockade. 2014researchers from the massachusetts general hospital cancer center in boston have reported on a method for studying treatment resistance that may identify combinations of targeted therapies that can help to combat resistance in some ent helps young women preserve their fertility during breast cancer chemotherapy.
2014researchers have found that young women with breast cancer were able to better preserve their fertility during cancer treatments by using hormone-blocking drug injections that put them into temporary menopause. The results announced today at the annual meeting of the american society of clinical oncology in chicago are from the prevention of early menopause study (poems), a clinical trial sponsored by study demonstrates that a new cancer immunotherapy method could be effective against a wide range of cancers. 2014a new method for using immunotherapy to specifically attack tumor cells that have mutations unique to a patient's cancer has been developed by nci launches trial to assess the utility of genetic sequencing to improve patient outcomes. The molecular profiling based assignment of cancer therapeutics, or m-pact, trial is one of the first to use a randomized trial design to assess if assigning treatment based on genetic screening can improve the rate and duration of response in patients with advanced solid studies demonstrate that modified t cells are effective in treating blood-borne cancers. Nci, presented findings from two clinical trials evaluating the use of genetically modified immune system t cells as cancer therapy. These reports represent important advances in the understanding of gene therapy for treatment of advanced blood-borne mouse study finds gut microorganisms may determine cancer treatment outcome. 2013an intact gut commensal microbiota, which is a population of microorganisms living in the intestine, is required for optimal response to cancer therapy, according to a mouse study by scientists at the national cancer institute (nci). 2013hodgkin lymphoma survivors who received certain radiation and chemotherapy regimens have been found to be at increased risk of subsequently developing stomach : a single drug target shows promise in multiple cancers. Trametinib has had encouraging results in patients with advanced melanoma, and selumetinib has been tested in patients with advanced thyroid and ovarian research is needed on what patients being treated for cancer should eat. 2013a survey of online recommendations shows there is a need for more research on the optimal nutritional approaches for patients being treated for cancer. 2013scientists have overcome a major impediment to the development of effective stem cell therapies by studying mice that lack cd47, a protein found on the surface of both healthy and cancer cells. 2013more often than not, cancer immunotherapies that work in adults are used in modified ways in children. Seldom are new therapies developed just for children, primarily because of the small number of pediatric patients relative to the adult cancer patient population.
2013a new study describes the pattern of risk for chemotherapy-related acute myeloid leukemia among adult cancer survivors over the past three decades who have previously been treated with chemotherapy for other cancers. 2012nih researchers have discovered a significant new mechanism of action for a class of chemotherapy drugs known as poly (adp-ribose) polymerase inhibitors, or parp inhibitors. Prior to this study, parp inhibitors were thought to work primarily by blocking parp enzyme activity, thus preventing the repair of dna damage and ultimately causing cell others may benefit: young cancer patients and survivors take part in oncofertility research. Researchers are using new and traditional ways to connect with and enroll young patients in clinical studies to assess and offset infertility caused by cancer and its ed nanoparticle tested in patients with cancer. 2012by packaging molecules of the chemotherapy drug docetaxel in nanoparticles, researchers aim to deliver a high dose directly to tumors and reduce the drug's toxicity. A trial to test the targeted nanoparticle is underway in x immune-based cancer treatment shows signs of progress. 2012genetically engineered t cells are being studied for the treatment of a variety of cancers. This article explores the challenges of moving the therapy from small clinical trials into the ng the conundrum of cachexia in cancer. 2011an article about why and how some patients with cancer develop a wasting syndrome that causes dramatic loss of muscle mass and substantial weight ng the rise of robotic surgery for prostate cancer. What the trend means for patients and the health care system is still a matter of study and dilemma: the debate over using placebos in cancer clinical trials. 2011many patients and researchers assert that in cancer clinical trials, placebos are inappropriate and that all participants should receive active treatment. But with the emergence of molecularly targeted anticancer agents, some cancer researchers believe placebo-controlled trials are now feasible and, in some cases, igating nature's mysteries for drug development. 2011more than half of the drugs approved to treat cancer come from a natural product or a natural product prototype.
Scientists in nci-frederick's natural products branch are exploring ways to harness chemicals produced by marine invertebrates, other animals, plants, and microbes for cancer drug ity still possible for many male cancer survivors, study finds. 2011some male survivors of childhood cancer who were thought to be sterile may be able to conceive children thanks to a surgical ving fertility while battling cancer. Researchers are developing decision aids to help patients make an informed, carefully considered decision about ines urge exercise for cancer patients, survivors. A panel of experts in cancer, fitness, obesity, and exercise training convened by the american college of sports medicine is spreading what they believe to be one of the most important messages for cancer patients and survivors: avoid ming age limits in cancer clinical trials. Nci researchers are studying how patients hear about trials, whether they discuss enrollment with their providers, and the roles they play in deciding to participate in a approves first therapeutic cancer vaccine. 2010sipuleucel-t (provenge) is a relatively nontoxic treatment option for men with hormone-resistant or castration-resistant prostate cancer. The fda's approval of the vaccine represented the first proof of principle that immunotherapy can work in ng on older cancer patients: a clinical need and a research necessity. 2010older patients metabolize drugs differently, are more likely to have other illnesses, and are more prone to problems that can influence cancer treatment efficacy. Researchers are now studying and altering their approach to caring for older herapy-induced peripheral neuropathy. 2010the pain and discomfort caused by peripheral neuropathy is one of the most common reasons that cancer patients stop their treatment early. Researchers are working to improve new screening, treatment, and prevention options for sing the biological activity of natural products. 2009researchers have been intrigued by the potent and beneficial biological activity shown by some natural products and are testing ways to incorporate them into standard and experimental cancer treatment regimens, both to enhance the anticancer effects of therapy and reduce side therapy for cancer. 2009public interest in this form of radiation therapy is growing, but members of the medical and research communities are concerned that enthusiasm for this promising therapy may be getting ahead of the y supplements and cancer treatment: a risky mixture.
2009some patients with cancer turn to dietary supplements advertised as having anticancer effects or being supportive of general health. But these biologically active compounds may interact dangerously with chemotherapy, radiation, or other cancer dema after cancer: how serious is it? 2007an article about a side effect of cancer treatment that causes lymph to build up in the extremities and cause pain: helping patients help themselves. 2006researchers are focusing on patient education as an important component in overcoming barriers to cancer pain icating about cancer pain. 2005patients with cancer may be reluctant to discuss their pain with their doctors for a variety of reasons. Nci sponsors research that examines the barriers that prevent patients from talking about out us cancer newsscience blognew immunotherapy discovery could give treatments the precision they immunotherapy discovery could give treatments the precision they ry: science blog march 3, 2016 alan worsley24 growth mirrors darwin's theory of the past few years, immunotherapies – treatments which harness the power of the immune system to fight cancer – have been making headlines around the powerful new weapons are exciting because once the immune system has ‘locked-on’ to a cancer cell it’s persistent and ruthless in taking it out. Some have even suggested they can cure certain the biggest challenges for immunotherapy have been identifying which molecules on the cancer cells are the best targets, as well as how to get past cancer’s now, the immunotherapy treatments available to patients are powerful-but-blunt weapons, which in some cases can result in a number of potentially serious side ’s urgently needed are treatments that can guide immune cells to specifically attack a tumour, while leaving healthy cells today, cancer research uk scientists have published a new study in the journal science that may have uncovered the intelligence needed to precisely guide these new before we go into detail about what they found, and its implications for future research, let’s recap how different immunotherapies g the immune system spot the years, researchers have tried many different approaches to turn the immune system against cancer, such as cutting the brakes on immune cells, flagging cancer cells for destruction, or genetically engineering a patient’s immune cells to directly target cancer cells. Credit: flickr/cc by most of these depend on the immune system being able to recognise cancer cells as the true threat that they are. Specialised immune cells, called t-cells, can then spot these antigens, releasing signals that destroy the damaged cell if the antigens aren’t looking the way they dna faults inside cells that lead to cancer can also change how proteins ‘look’ to the immune system. So, theoretically, once the immune system recognises a cancer specific antigen, it should destroy all cancer cells that carry that flag. Essentially there are two competing ideas”, says dr sergio quezada, from university college london, and one of the world’s leading experts in how the immune system interacts with immune cells waste precious resources chasing after antigens that aren’t present on the surface of all the cancer cells then they risk missing parts of the tumour entirely. If immune cells waste precious resources chasing after antigens that aren’t present on the surface of all the cancer cells then they risk missing parts of the tumour entirely. But to answer this question would require an enormous amount of data from patients’ ately, another cancer research uk- funded team, working on a different challenge, have developed a set of tools that might help provide that francis crick institute’s professor charlie swanton is one of the world’s leading experts in the genetics behind how tumours grow and change, and the gene faults (mutations) that fuel this.
One of the reasons why some cancers – lung cancer and melanoma in particular – are so hard to treat is because they evolve so rapidly they quickly outpace the drugs we use to stop them,” he says. These cancers have been exposed to many dna damaging substances – such as cigarette smoke or uv light – and this damage gives rise to many different faults in their dna. As the data has poured in, swanton’s team had begun to wonder whether this overwhelming complexity, which can make cancers so resistant to certain treatments, may be the very thing that reveals it to the immune system. But if these early origins of a cancer’s development are also being presented as antigens on the surface of tumour cells, they could provide an ideal target for the immune system to swanton and quezada’s team’s joined forces to find out if this is the had suspected that the diversity of mutations we see in tumour evolution would be reflected by the antigens present on the cancer cells – but until now we had no proof. Turning this computational firepower to analysing cancer’s immune signature was a new idea: “we have been using this type of analysis to predict what sorts of mutations are present across the tumour, so we wondered whether we could also use it to look for antigens shared on all tumour cells,” mcgranahan explains. We had suspected that the diversity of mutations we see in tumour evolution would be reflected by the antigens present on the cancer cells – but until now we had no proof. Test this, they turned to a treasure trove of data called the cancer genome atlas (tcga), which records genetic data on thousands of patients who’ve been treated for cancer, alongside how they fared after these data from over 200 patients with one of two different types of lung cancer (adenocarcinoma and squamous cell carcinoma) they predicted how many antigens a tumour contained, and the proportion that were common throughout the ngly, in the lung adenocarcinoma patients, they saw that when the tumour cells contained many antigens that were shared across the tumour, the patients generally fared in people with squamous cell carcinoma the team didn’t find the same association. Instead, the squamous cell carcinoma cells tended not to display antigens on their surface – providing them with a potential way of escaping the immune to understand why there might be an association at all, the researchers took a closer look at tumour samples from two patients with lung cancer that had a similar smoking first running their antigen prediction analysis on the two tumour samples, the team then produced hundreds of these predicted antigens in the lab to ‘fish out’ any immune cells in the tumour samples that recognised and latched on to three antigens were up to the job. And, crucially, each of these antigens had originally been predicted to be present on every cancer cell in the tumour sample – as the animation below the video on if these immune cells were capable of recognising every cell in the tumour, why didn’t they kill it? Down cancer’s y, these tumours contained immune cells capable of recognising the cancer cells as dangerous, but somehow the cancer was keeping them at s use tricks to escape destruction by immune cells, including releasing signals that suppress immune cells. Crucially, they found that tumours containing lots of antigens that were shared across the tumour also produced high levels of an immune-dampening molecule called suggests that while these cancer cells should be highly vulnerable to immune attack – because they are covered in shared antigens – they have to find a way of holding the immune system at bay to test this idea further, the team then looked at data from patients in a us study, who’d received a checkpoint immunotherapy drug called pembrolizumab (keytruda), which blocks the immune cells from receiving the pd-l1 ‘stop signal’. Running their antigen prediction programme, the team then grouped the tumours into those that had many antigens on all cancer cells and those that carried lots of different tumour antigens on their 13 patient tumours that had many shared antigens, 12 had responded well to the immunotherapy treatment. Tumours with many shared antigens attracted immune cells, which the cancer cells then had to suppress to stay alive.
But if drugs were given that break through the cancer’s defences, patients whose cancers had antigens that were found across the tumour appeared to benefit the immediate implications of this work are for researchers developing new immunotherapies. But if the target isn’t present on all the cancer cells, then the treatment risks leaving some cells behind, where they can regroup and the tumour can come next step is to work out how doctors could use the team’s prediction programmes to make better decisions over which treatments to offer gh it’s early days, it offers hope that we might just be able to turn the tide against advanced cancer – something we desperately want for our patients. Professor charlie swanton, cancer research some cases, cancers may be hiding the ‘flags’ that immune cells recognise, so other treatments may need to be if scientists can harness the immune cells that do recognise these targets it could lead to new swanton, the study reveals a welcome weakness behind cancer’s sometimes baffling complexity. It’s incredibly exciting,” he adds, “and although it’s early days, it offers hope that we might just be able to turn the tide against advanced cancer – something we desperately want for our patients. Quezada and their teams are now working to turn this idea into something that could be applied to many more cancers, finding unique targets on all cancer cells and not the healthy therapy is an incredibly exciting weapon against cancer – as recent headlines make to the combined ingenuity of two of our teams of cancer researchers, we may have found the tools necessary to give immunotherapy the precision guidance that patients so desperately ahan, et al. Want the doctor who is the responsible to the search to pay litlle attention what i will say here: i believe that cancer should be look at in his own envirement because they suffer mutations along their grow. It means that the cancer don’t need to be remove from the paciente , but with the modern tecnology the doctor will see it on the body to discover the principal mother cell who starts the process. I had a lung scan done after my second session of chemo and was told that the cancer had shrunk. I had another scan done after my radiotherapy and was told that the cancer had grown. I was told before my treatment that they would not operate to remove the growth as they thought it may be impinging on the pulmary artery, but the scan showed that it was not, i have asked if it would be possible to operate to either remove the cancer or possibly the lung and was told that surgery was not possible and i must continue with chemo even though it may not slow down the growth. A very good news ,but who wants to know more please watch the truth about cancer,there are so many ways to beat cancer,it gives me hope,cause i am cancer gene dan and god bless i hope one day it’ will be finish badnes to ating reading wonderful to hear so many dedicated people are doing such amazing research and continuing to find out sources of and workings of so many cancers. Report easy for people who have very little science or medical you cancer researchers for giving hope to all of us who live with cancer. We do it in the name of our employees and the many friends and family who are afflicted with cancer.
Why the world can get together for climate change but not for cancer is beyond me. If there would be one benefit from living in a totally globalised world of call centres and sameness, it would be the world uniting to equally halve defense budgets and spending everything on cancer research. Please let this all happen in time to cure my lovely done cancer research for such ground breaking research. Warm thanks to the encouraging to hear the great progress being made in understanding and treating cancer, especially new approaches to add to radiotherapy and chemotherapy. Gives hope to those of us in remission and underlines how vital it is to ensure fundraising efforts continue to support the research efforts of those working on our is the most progressive and heartening news that i have read in the 32 years since my wife died of breast cancer. I have family and friends that have died from cancer and done are in the battle now—on the front in three of us will be diagnosed with cancer…its in all our interests to support the cancer research charities by donating regular amounts (however small). Very good article that gets to the crux of the issue of what the researchers found. Things you might not know about alcohol and and cancer – what does the evidence say? Meat and cancer – what you need to digest – breast cancer drugs, alcohol pricing, ‘indulgent grandparents’, and… coffee (again)? Once in a career feeling’ as trial shows offering prostate cancer drug earlier improves survival. Topics research uk-funded the latest blog headlines delivered to your newsnews digest – nhs announcements, the budget, experimental treatments and… alcoholic jelly? 25, 2017category: science blog our milestones: nudging breast cancer radiotherapy in the right directionnovember 24, 2017category: science blog gut bacteria might hitch a ride with spreading bowel cancer cellsnovember 24, 2017category: news report experimental drug trial seeks to improve treatment for head and neck cancernovember 24, 2017category: press release browse all cover the latest cancer research, including that funded by the charity. We also highlight other relevant material, debunk myths and media scares, and provide links to other helpful our terms and from cancer research uk science blog by cancer research uk, is licensed under a creative commons attribution-noncommercial-sharealike would like your feedback, please fill in our out us cancer newsscience blognew immunotherapy discovery could give treatments the precision they immunotherapy discovery could give treatments the precision they ry: science blog march 3, 2016 alan worsley24 growth mirrors darwin's theory of the past few years, immunotherapies – treatments which harness the power of the immune system to fight cancer – have been making headlines around the powerful new weapons are exciting because once the immune system has ‘locked-on’ to a cancer cell it’s persistent and ruthless in taking it out.
We also highlight other relevant material, debunk myths and media scares, and provide links to other helpful our terms and from cancer research uk science blog by cancer research uk, is licensed under a creative commons attribution-noncommercial-sharealike would like your feedback, please fill in our survey.